AN2 Therapeutics, Inc
6 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| First-in-Human Trial of Oral AN2-502998 (NCT07024589) | AN2 Therapeutics, Inc | 2025-08-04 |
| An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis (NCT06089668) | AN2 Therapeutics, Inc | 2023-11-01 |
| A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects (NCT05995444) | AN2 Therapeutics, Inc | 2023-06-05 |
| Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease (NCT05327803) | AN2 Therapeutics, Inc | 2022-05-20 |
| A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function (NCT05283746) | AN2 Therapeutics, Inc | 2022-02-21 |
| Phase 1 Study of Epetraborole Tablets (NCT04892641) | AN2 Therapeutics, Inc | 2021-06-10 |
Track AN2 Therapeutics, Inc automatically
Every clearance here is in the API, with alerts when new ones post.